L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease
Cell therapy is a promising treatment for Parkinson’s disease (PD), however clinical trials to date have shown relatively low survival and significant patient-to-patient variability. Glucagon Like Peptide-1 receptor (GLP-1R) agonists have potential neuroprotective effects on endogenous dopaminergic...
Main Authors: | Osama F. Elabi, Jeffrey S. Davies, Emma L. Lane |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/22/12346 |
Similar Items
-
GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease
by: Kallirhoe Kalinderi, et al.
Published: (2024-03-01) -
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease
by: Tung-Tai Kuo, et al.
Published: (2023-02-01) -
Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
by: Hiromi Sano, et al.
Published: (2023-06-01) -
GLP-1 agonists in treatment of obesity
by: Władysław Orłowski, et al.
Published: (2023-01-01) -
Better Outcomes with Intranigral versus Intrastriatal Cell Transplantation: Relevance for Parkinson’s Disease
by: Marine Droguerre, et al.
Published: (2022-04-01)